Table 1.
Clinicopathologic characteristics of patients with cHCC-CCA
| Clinical parameters | MVI-positive (n = 59) | MVI-negative (n = 60) | p value |
|---|---|---|---|
| Age (years) | 54.4 ± 10.5 | 53.9 ± 10.5 | 0.245 |
| Gender | 0.241 | ||
| Male | 44 (74.6) | 50 (83.3) | |
| Female | 15 (25.4) | 10 (16.7) | |
| Largest diameter (cm) | 0.261 | ||
| 1–2 cm | 8 (13.6) | 15 (25) | |
| 2–5 cm | 33 (55.9) | 31 (51.7) | |
| ≥ 5 cm | 18 (30.5) | 14 (23.3) | |
| Hepatitis B virus | 0.851 | ||
| Absent | 11 (18.6) | 12 (20) | |
| Present | 48 (81.4) | 48 (81.4) | |
| Cirrhosis | 0.940 | ||
| Absent | 35 (59.3) | 36 (60) | |
| Present | 24 (40.7) | 24 (40) | |
| AFP | 0.020* | ||
| ≤ 400 ng/mL | 42 (71.2) | 53 (88.3) | |
| > 400 ng/mL | 17 (28.8) | 7 (11.7) | |
| PIVKA-II | 0.625 | ||
| ≤ 40 | 22 (37.3) | 25 (41.7) | |
| > 40 | 37 (62.7) | 35 (58.3) | |
| CA19-9 | 0.127 | ||
| ≤ 39 ng/mL | 50 (84.7) | 44 (73.3) | |
| > 39 ng/mL | 9 (15.3) | 16 (26.7) | |
| CEA | 0.319 | ||
| ≤ 10 ng/m | 59 (100) | 59 (98.3) | |
| > 10 ng/m | 0 (0) | 1 (1.7) | |
| ALT, U/L | 26 (18,37) | 22 (16,93) | 0.713 |
| AST,U/L | 27 (20,34) | 23 (18,51.3) | 0.786 |
| GGT, U/L | 44 (28,77) | 41.5 (17.3,71.5) | 0.282 |
| ALB, g/L | 42.3 ± 3.3 | 43.0 ± 3.6 | 0.438 |
| Pro-ALB, g/L | 206.6 ± 56.1 | 222.7 ± 58.6 | 0.334 |
| TiBL, μmol/L | 13.5 ± 4.3 | 15.1 ± 5.7 | 0.231 |
| DBL, μmol/L | 5.1 ± 1.9 | 5.6 ± 2.7 | 0.427 |
| NLR | 0.235 | ||
| ≤ 1.94 | 30 (50.8) | 24 (40) | |
| > 1.94 | 29 (49.2) | 36 (60) | |
| PLR | 0.272 | ||
| ≤ 124.70 | 42 (71.2) | 37 (61.7) | |
| > 124.70 | 17 (28.8) | 23 (38.3) | |
| LMR | 0.074 | ||
| ≤ 3.51 | 12 (20.3) | 21 (35) | |
| > 3.51 | 47 (79.7) | 39 (65) | |
| AAPR | 0.025* | ||
| ≤ 0.75 | 50 (84.7) | 58 (96.7) | |
| > 0.75 | 9 (15.3) | 2 (3.3) | |
| APRI | 0.014* | ||
| ≤ 0.08 | 10 (16.9) | 2 (3.3) | |
| > 0.08 | 49 (83.1) | 58 (96.7) | |
| ANRI | 0.013* | ||
| ≤ 4.63 | 15 (25.4) | 5 (8.3) | |
| > 4.63 | 44 (74.6) | 55 (91.7) | |
| AGLR | 0.074 | ||
| ≤ 256.52 | 26 (44.1) | 17 (28.3) | |
| > 256.52 | 33 (55.9) | 43 (71.7) | |
| GPRI | 0.156 | ||
| ≤ 0.39 | 39 (66.1) | 32 (53.3) | |
| > 0.39 | 20 (39.9) | 28 (46.7) | |
| NRPI | 0.037* | ||
| ≤ 0.03 | 46 (78) | 55 (91.7) | |
| > 0.03 | 13 (22) | 5 (8.3) | |
| GAR | 0.082 | ||
| ≤ 0.92 | 33 (55.9) | 24 (40) | |
| > 0.92 | 26 (44.1) | 36 (60) | |
| GLR | 0.169 | ||
| ≤ 28.10 | 33 (55.9) | 26 (43.3) | |
| > 28.10 | 26 (44.1) | 34 (56.7) | |
Data are presented as the mean ± standard deviation, median (25th, 75th percentile), and the number of patients (%). The p value represents the statistical difference between the MVI-positive and MVI-negative groups
HBV hepatitis B virus, AFP α-fetoprotein, PIVKA-II protein induced by vitamin K absence or antagonist-II, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyltranspeptidase, ALB albumin, Pro-ALB pro-albumin, TBL total bilirubin, DBL direct bilirubin, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, LMR lymphocyte to monocyte ratio, AAPR albumin-to-alkaline phosphatase ratio, APRI aspartate aminotransferase to platelet ratio index, ANRI aspartate aminotransferase-to-neutrophil ratio index, AGLR (alkaline phosphatase + γ-glutamyltranspeptidase) to lymphocyte ratio, GPRI γ-glutamyltranspeptidase to platelet ratio index, NRPI neutrophil to prealbumin ratio index, GAR γ-glutamyltranspeptidase to albumin ratio, GLR γ-glutamyltranspeptidase to lymphocyte ratio, MVI microvascular invasion
*Indicate statistical significance